{'fraction_non_alphanumeric': 0.019498607242339833, 'fraction_numerical': 0.0, 'mean_word_length': 5.145299145299146, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Biomarkers in Parkinson's disease: a venture capitalist's perspective.

The emergence of biomarkers linking disease and treatment effects in a clear manner presents an opportunity to change the current drug development paradigm, which could lead to more cost-efficient and higher-quality clinical trials. This has raised the hopes of venture capital investors, who may be able to better navigate the stormy and risky sea of early-stage life science investments, to find a way out of the current funding crisis for novel, nonvalidated drugs and their clinical development. The following survey paints a snapshot of the current perception of biomarkers as a paradigm changer in the eyes of the venture capital community.